Editorial: Mitochondrial medicine special issue

Affiliations

¹ Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
² Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
³ Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Howard Hughes Medical Institute and Departments of Molecular Biology and Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
⁴ Mitochondrial Research Group, UCL Great Ormond Street Institute of Child Health, London, UK; Metabolic Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Editorial

Patrick F Chinnery et al. J Inherit Metab Dis. 2021 Mar.

. 2021 Mar;44(2):289-291.

doi: 10.1002/jimd.12374.

¹ Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
² Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
³ Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Howard Hughes Medical Institute and Departments of Molecular Biology and Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
⁴ Mitochondrial Research Group, UCL Great Ormond Street Institute of Child Health, London, UK; Metabolic Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

No abstract available

References

1. Fox BC, Slade L, Torregrossa R, et al. The mitochondria-targeted hydrogen sulfide donor AP39 improves health and mitochondrial function in a C. elegans primary mitochondrial disease model. J Inherit Metab Dis. 2020. https://doi.org/10.1002/jimd.12345.
1. Hirano M, Berardo A, Barca E, et al. Regulatory environment for novel therapeutic development in mitochondrial diseases. J Inherit Metab Dis. 2020a. https://doi.org/10.1002/jimd.12353.
1. Thompson PW. Developing new treatments in partnership for primary mitochondrial disease: what does industry need from academics, and what do academics need from industry? J Inherit Metab Dis. 2020. https://doi.org/10.1002/jimd.12326.
1. Koga Y, Povalko N, Inoue E, et al. A new diagnostic indication device of a biomarker growth differentiation factor 15 for mitochondrial diseases: from laboratory to automated inspection. J Inherit Metab Dis. 2020. https://doi.org/10.1002/jimd.12317.
1. Goldstein A, Rahman S. Seeking impact: global perspectives on outcome measure selection for translational and clinical research for primary mitochondrial disorders. J Inherit Metab Dis. 2020. https://doi.org/10.1002/jimd.12320.